Saniona AB (publ) Smedeland 26B. DK-2600 Glostrup. Denmark.

Saniona and Boehringer Ingelheim entered the ongoing research collaboration in 2020. The objective is to identify new treatment options for schizophrenia with a new class of therapeutics, which modulates an undisclosed CNS ion channel target. Boehringer Ingelheimer has exclusive worldwide rights to research, develop, manufacture, and commercialize therapeutics identified through the collaboration.

Saniona may receive up to EUR76.5 million in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration. In addition, Saniona receives research funding during the joint research period. During the first year of the extension period, Saniona expects to receive research funding of around SEK 12.3 million (EUR1.1 million).

The total research funding under the company's collaborations with Boehringer Ingelgen and AstronauTx is consequently expected to increase to about SEK 27.3 million (EUR 2.4 million) on annual basis.